Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Other Non-Current Liabilities (2021 - 2025)

Abeona Therapeutics has reported Other Non-Current Liabilities over the past 11 years, most recently at $18.9 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 40.96% year-over-year to $18.9 million; the TTM value through Dec 2025 reached $18.9 million, down 40.96%, while the annual FY2025 figure was $18.9 million, 40.96% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $18.9 million at Abeona Therapeutics, down from $22.6 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $32.0 million in Q4 2024 and troughed at $200000.0 in Q1 2022.
  • A 5-year average of $15.4 million and a median of $18.9 million in 2025 define the central range for Other Non-Current Liabilities.
  • Biggest five-year swings in Other Non-Current Liabilities: soared 13461.0% in 2023 and later crashed 97.43% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $9.0 million in 2021, then soared by 118.24% to $19.7 million in 2022, then surged by 59.5% to $31.4 million in 2023, then grew by 2.11% to $32.0 million in 2024, then tumbled by 40.96% to $18.9 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for ABEO at $18.9 million in Q4 2025, $22.6 million in Q3 2025, and $30.2 million in Q2 2025.